Publication Instructions:

BMT CTN Protocol 1301
- Primary and Ancillary Studies –

The requirements below are for publications and presentations made pursuant to the primary BMT CTN Study and the 1301 ancillary studies.

Acknowledgment Requirements:

For all Publications, Reports, Presentations, Symposiums, etc.

"Support for this study was provided by grant #U10HL069294 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute, along with contributions by Miltenyi Biotec, GmbH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the above mentioned parties."

The following language should be inserted in the acknowledgements for all BMT CTN Studies that utilize CIBMTR data:
The CIBMTR registry is supported primarily by the U24-CA76518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases and from HHSH234200637015C (HRSA/DHHS) to the Center for International Blood and Marrow Transplant Research.

Review Requirements:

For all Publications, Reports, Presentations, Symposiums, etc.

BMT CTN: Abstracts, presentations, and proposed publications relating to data obtained from BMT CTN protocols or to activities of BMT CTN Committees or Protocol Teams are to be submitted to the DCC for review.

Miltenyi: Provide Miltenyi a draft copy of all publications and a summary of data resulting from the study when such information is ready to be made available to the public and prior to any publication or presentation of such information. Miltenyi will have up to 30 consecutive days to review information, submit questions, and provide comments with the understanding that all decisions regarding publication will be at the sole discretion of the BMT CTN, although BMT CTN agrees to reasonably consider Miltenyi's comments.

If Miltenyi objections relate to information provided by the Miltenyi as Miltenyi's Proprietary Information or to inaccurate information, such information shall be removed from the publication.

With regard to any information included in such publication or presentation relating to the CliniMACS device that may have patentable merit and to which Miltenyi has any rights, the BMT CTN DCC shall delay the publication or presentation for a period of up to thirty (30) days to allow for the filing of a patent application.

Questions regarding the above requirements may be directed to the Data Coordinating Center, NMDP Contracts & Procurement Department at NMDP_BMTCTN_Pub@nmdp.org.